## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Rachael ANCLIFF et al. Conf. No. 5647
Serial No.: 10/531,758 Art Unit: 1624

Filing Date: April 14, 2005 Examiner: Coleman, Brenda Libby

For: Substituted Piperazines, (1,4) Diaszepines, and 2,5-Diazabicyclo (2.2.1) Heptaines as Histamine

H1 and/or H3 Antagonists or Histamine H3 Reverse Antagonists

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

		— 11 - 11 - 11 - 11 - 11 - 11 - 11 - 11						
	[X] Copies of the references are enclosed							
	[ ] Copies of the references were submitted in parent application Serial No  (37 CFR 1.98(d))							
	- a	A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.						
A.	[X]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).						
	OR	, , , , , , , , , , , , , , , , , , , ,						
	[1	The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).						
B.	[]	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:  (1) a final action under § 1.113 or (2) a notice of allowance under § 1.311, whichever occurs first.						
	[]	Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.						
	[]	Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).						

## Atty. Docket No. P33126USw

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [ ] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- The petition fee set forth in  $\S 1.17(i)(1)$  (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No. 07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek
Attorney of Record
Registration No. 39,009

Date: 11-15-2006

Customer No. 23347 GlaxoSmithKline

Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

FORM PTO					SERIAL NO.		10/531,75	58		
INFORMAT	TION :	DISCLOSURE ST.	ATEMENT		FILING DATE		April 14,	April 14, 2005		
					APPLICANT		Rachael	Rachael Ancilff et al.		
					GROUP		1624	1624		
					EXAMINER		Coleman	Coleman, Brenda Libby		
					ATTORNEY DOCKET NO. P33126USw					
U.S. PATENT DOCUMENTS										
Examiner Initiak		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate		
	1.	5,880,128	03/1999	DOLL et al.						
			_							
			C	Continue on p	age					
		· · · · · · · · · · · · · · · · · · ·		N PATENT	DOCUMENTS					
		Document Number	Publication Date		Country	Class	Subclass	Translation Yes   No		
	2.	DE 4410822	09/1995	DE				х		
	3.	WO 95/25443	09/1995	PCT				Х		
	4.	WO 97/26252	07/1997	PCT				Х		
	5.	WO 99/41242	08/1999	PCT				X		
	6.	JP 2002-173426	06/2002	JP				X		
	7.	WO 04/094441	11/2004	PCT				X		
	<u> </u>									
	<u> </u>									
	L									
			c	ontinue on p	age					
		OTHER DOCUM	ENTS (Includi	ng Author,	Title, Journal-Dat	e, Page Num	ber, Etc.)			
	<b>⊢</b> —	<del> </del> -								
	├—	<del></del>	1							
	—									
<u>-</u> -	<del></del>									
	⊢				<del></del>					
	$\vdash$									
	$\vdash$	-				_				
	_									
	_									
	<del> </del>	<del>                                     </del>		_						
		<del></del>								
_				ontinue on p	2270					
EXAMINER				zonanae on p	7age	DATE	ONSIDEREI			
						DAIL	ONSIDEKEI	'		
EXAMINER citation if not	Initia	al if citation consider formance and not co	red, whether or r	not citation is	s in conformance w	rith MPEP § 6	09; Draw line	through		